Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 10/20 | 0.44 |
| ▸ | ROCK2 | O75116 | 7/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.41 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.40 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4777271 | 0.89 | ROCK1 (0.48) | TRPV1ROCK1ROCK2 | |
| SCHEMBL4726382 | 0.88 | ROCK1 (0.46) | ROCK1ROCK2 | |
| SCHEMBL4726471 | 0.88 | ROCK1 (0.47) | TRPV1ROCK1ROCK2 | |
| SCHEMBL4725491 | 0.88 | ROCK1 (0.47) | TRPV1ROCK1ROCK2 | |
| SCHEMBL4776809 | 0.86 | ROCK1 (0.46) | ROCK1ROCK2 | |
| SCHEMBL4725532 | 0.86 | MEN1 (0.46) | ROCK1ROCK2 | |
| SCHEMBL4780457 | 0.84 | ROCK1 (0.45) | TRPV1ROCK1ROCK2 | |
| SCHEMBL4779953 | 0.83 | ROCK1 (0.58) | ROCK1ROCK2 | |
| SCHEMBL4726466 | 0.82 | ROCK1 (0.49) | ROCK1ROCK2 | |
| SCHEMBL4725670 | 0.82 | ROCK2 (0.55) | ROCK1ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | claimed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | claimed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| US-8716320-B2 | Antibacteriall heterocyclic ureas | REPLIDYNE, INC. (US) | 2014-05-06 | — | — | US | disclosed |
| US-20080207703-A1 | Antibacterial heterocyclic ureas | REPLIDYNE, INC. (US) | 2008-08-28 | — | — | US | disclosed |
| WO-2008011191-A1 | ANTIBACTERIAL HETEROCYCLIC UREAS | REPLIDYNE, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207703-A1 | Antibacterial heterocyclic ureas | UMPS, UROD, UGP2 | TRPV1 3935/4885ROCK1 4331/4885ROCK2 4405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.